Riboflavin Supplementation And Biomarkers Of Cardiovascular Disease In The Elderly
| Effect | None |
| Trial Design | Double blind |
| Trial Length | 2-4 Weeks |
| Number of Subjects | 42 |
| Sex | Both Genders |
| Age Range | 45-64, 65+ |
| Body Types | Overweight |
Four weeks supplementation of 10mg riboflavin supplementation in elderly subjects with suboptimal riboflavin status (assessed by EGRAC) was able to reduce total homocysteine levels in serum, but was without effect on C-reactive protein or other biomarkers of cardiovascular health.
